Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016

  • ID: 3961145
  • Report
  • 136 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aciont Inc.
  • Astellas Pharma Inc.
  • Charlesson LLC.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • MeiraGTx Limited
  • MORE
Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016

The latest Pharmaceutical and Healthcare disease pipeline guide Dry (Atrophic) Macular Degeneration – Pipeline Review, H2 2016, provides an overview of the Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline landscape.

Dry atrophic macular degeneration is generally characterized by a slow but progressive visual loss. This is characterized by yellow spots under the retina, called drusen, which are accumulations of metabolic waste products. Symptoms include blurred or decreased central close-up and distance vision, blind spots, micropsia and straight lines look distorted. Predisposing factors include age and family history.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Dry (Atrophic) Macular Degeneration – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dry (Atrophic) Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Dry (Atrophic) Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 10, 2, 14, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Dry (Atrophic) Macular Degeneration.

Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dry (Atrophic) Macular Degeneration (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Dry (Atrophic) Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dry (Atrophic) Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dry (Atrophic) Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dry (Atrophic) Macular Degeneration (Ophthalmology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dry (Atrophic) Macular Degeneration (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aciont Inc.
  • Astellas Pharma Inc.
  • Charlesson LLC.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • MeiraGTx Limited
  • MORE
Introduction

Dry (Atrophic) Macular Degeneration Overview

Therapeutics Development

Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview

Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis

Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies

Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes

Dry (Atrophic) Macular Degeneration - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Dry (Atrophic) Macular Degeneration - Products under Development by Companies

Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes

Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development

Aciont Inc.

Alimera Sciences, Inc.

Allergan Plc

Apellis Pharmaceuticals Inc

Astellas Pharma Inc.

Benitec Biopharma Limited

Biophytis SAS

Catalyst Biosciences, Inc.

Cell Cure Neurosciences, Ltd.

Charlesson LLC.

Foamix Pharmaceuticals Ltd.

Genentech Inc

GenSight Biologics S.A.

GlaxoSmithKline Plc

Icon Bioscience, Inc.

Inception Sciences, Inc.

Johnson & Johnson

Kodiak Sciences Inc.

MacuCLEAR Inc

MeiraGTx Limited

Novartis AG

Ophthotech Corp.

Orphagen Pharmaceuticals, Inc.

pSivida Corp.

Samumed LLC

Sucampo Pharmaceuticals, Inc.

Sun Pharma Advanced Research Co Ltd

Dry (Atrophic) Macular Degeneration - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

A-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APL-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avacincaptad pegol sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBAMD-231 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIO-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brimonidine tartrate implant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLG-561 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLT-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNTO-2476 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Age Related Macular Degeneration - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EG-30 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FMX-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Dry Macular Degeneration and Retinitis Pigmentosa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Ocular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-030 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-933776 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICR-14967 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KSI-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lampalizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MA09-hRPE - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MC-1101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methotrexate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OCU-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONL-1204 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OpRegen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OpRegen Plus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RC-1 Alpha - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RST-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Dry AMD and Wet AMD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for AMD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Dry Age-Related Macular Degeneration - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Dry AMD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tesidolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

unoprostone isopropyl - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VM-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dry (Atrophic) Macular Degeneration - Dormant Projects

Dry (Atrophic) Macular Degeneration - Discontinued Products

Dry (Atrophic) Macular Degeneration - Product Development Milestones

Featured News & Press Releases

Aug 30, 2016: RetroSense Therapeutics Granted Patent on Proprietary Method for Restoring Vision using Optogenetics

May 05, 2016: RetroSense Therapeutics to Highlight Contributions to Gene Therapy Research in Upcoming Conferences

Apr 12, 2016: BIOPHYTIS to Present Pre-Clinical Data on BIO 201 at Upcoming Scientific Conference

Nov 17, 2015: Biophytis establishes New subsidiary to accelerate clinical development of Maculia

Oct 01, 2013: Roche to present data on Lampalizumab at investor event

Aug 27, 2013: Roche’s lampalizumab phase II data shows benefit in patients with the advanced form of dry age-related macular degeneration

Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials

May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells

Apr 15, 2013: ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt’s Macular Dystrophy

Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy

Mar 14, 2013: Advanced Cell Technology Receives DSMB Approval To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials Using hESC-derived RPE Cells

Feb 15, 2013: OgenX Therapeutics Announces Presentation Of RAVEN-1 Trial Final Results At Snowmass Ophthalmology Conference

Jan 08, 2013: Advanced Cell Technology Achieves Clinical Milestone

Nov 28, 2012: ACT Completes Higher-Dosage Cohort In Both US Clinical Trials Using Retinal Pigment Epithelial Cells

Aug 02, 2012: ACT Announces First Dry Age-Related Macular Degeneration Patient Treated With Higher Dosage Of Embryonic Stem Cell-Derived RPE Cells

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Dry (Atrophic) Macular Degeneration, H2 2016

Number of Products under Development for Dry (Atrophic) Macular Degeneration - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Aciont Inc., H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Alimera Sciences, Inc., H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Allergan Plc, H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Apellis Pharmaceuticals Inc, H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Astellas Pharma Inc., H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Benitec Biopharma Limited, H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Biophytis SAS, H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Catalyst Biosciences, Inc., H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Cell Cure Neurosciences, Ltd., H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Charlesson LLC., H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Genentech Inc, H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by GenSight Biologics S.A., H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by GlaxoSmithKline Plc, H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Inception Sciences, Inc., H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Johnson & Johnson, H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Kodiak Sciences Inc., H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by MacuCLEAR Inc, H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by MeiraGTx Limited, H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Novartis AG, H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Ophthotech Corp., H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by pSivida Corp., H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Samumed LLC, H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline by Sun Pharma Advanced Research Co Ltd, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Dry (Atrophic) Macular Degeneration - Dormant Projects, H2 2016

Dry (Atrophic) Macular Degeneration - Dormant Projects (Contd..1), H2 2016

Dry (Atrophic) Macular Degeneration - Dormant Projects (Contd..2), H2 2016

Dry (Atrophic) Macular Degeneration - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Dry (Atrophic) Macular Degeneration, H2 2016

Number of Products under Development for Dry (Atrophic) Macular Degeneration - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aciont Inc.
  • Alimera Sciences, Inc.
  • Allergan Plc
  • Apellis Pharmaceuticals Inc
  • Astellas Pharma Inc.
  • Benitec Biopharma Limited
  • Biophytis SAS
  • Catalyst Biosciences, Inc.
  • Cell Cure Neurosciences, Ltd.
  • Charlesson LLC.
  • Foamix Pharmaceuticals Ltd.
  • Genentech Inc
  • GenSight Biologics S.A.
  • GlaxoSmithKline Plc
  • Icon Bioscience, Inc.
  • Inception Sciences, Inc.
  • Johnson & Johnson
  • Kodiak Sciences Inc.
  • MacuCLEAR Inc
  • MeiraGTx Limited
  • Novartis AG
  • Ophthotech Corp.
  • Orphagen Pharmaceuticals, Inc.
  • pSivida Corp.
  • Samumed LLC
  • Sucampo Pharmaceuticals, Inc.
  • Sun Pharma Advanced Research Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll